347 related articles for article (PubMed ID: 34643122)
1. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
Shadid M; Badawi M; Abulrob A
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
[TBL] [Abstract][Full Text] [Related]
2. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
Haque US; Yokota T
Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
[TBL] [Abstract][Full Text] [Related]
3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
4. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
5. Antisense drug discovery and development.
Yamamoto T; Nakatani M; Narukawa K; Obika S
Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846
[TBL] [Abstract][Full Text] [Related]
6. Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide.
Yeoh YQ; Amin A; Cuic B; Tomas D; Turner BJ; Shabanpoor F
Biomed Pharmacother; 2024 Jun; 175():116737. PubMed ID: 38749176
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
8. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing.
Le BT; Paul S; Jastrzebska K; Langer H; Caruthers MH; Veedu RN
Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2207956119. PubMed ID: 36037350
[TBL] [Abstract][Full Text] [Related]
9. Splicing therapy for neuromuscular disease.
Douglas AG; Wood MJ
Mol Cell Neurosci; 2013 Sep; 56():169-85. PubMed ID: 23631896
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen.
Imai S; Suda Y; Mori J; Sasaki Y; Yamada T; Kusano K
Drug Metab Dispos; 2023 Oct; 51(10):1428-1435. PubMed ID: 37468285
[TBL] [Abstract][Full Text] [Related]
11. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
13. Chemistry, structure and function of approved oligonucleotide therapeutics.
Egli M; Manoharan M
Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
[TBL] [Abstract][Full Text] [Related]
14. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
16. Viltolarsen for the treatment of Duchenne muscular dystrophy.
Roshmi RR; Yokota T
Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/Pharmacodynamic Modeling of a Cell-Penetrating Peptide Phosphorodiamidate Morpholino Oligomer in mdx Mice.
Mukashyaka MC; Wu CL; Ha K; Zhang J; Wood J; Foley S; Mastis B; Jungels N; Sun H; Shadid M; Harriman S; Hadcock JR
Pharm Res; 2021 Oct; 38(10):1731-1745. PubMed ID: 34671920
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.
Shabanpoor F; Hammond SM; Abendroth F; Hazell G; Wood MJA; Gait MJ
Nucleic Acid Ther; 2017 Jun; 27(3):130-143. PubMed ID: 28118087
[TBL] [Abstract][Full Text] [Related]
20. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
